Abstract: Sepsis-induced cardiomyopathy (SIC) is a serious complication caused by sepsis involving the target organ heart, and its definition and diagnostic criteria have not yet formed a consensus. Currently, the diagnosis of SIC relies on echocardiography and blood biomarkers. However, traditional biomarkers such as cardiac troponin (cTn) and B-type natriuretic peptide (BNP) have low specificity for diagnosing SIC. In recent years, a variety of novel biomarkers have emerged, which have significant clinical value in the diagnosis and prognosis of SIC. In this article, we summarize the research progress on novel biomarkers related to SIC.